Vilin Bio Med (NSE:VILINBIO) EBIT: ₹26.5 Mil (TTM As of Mar. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

NSE:VILINBIO Vilin Bio Med Ltd NSE:VILINBIO
69 GF Score
Price ₹44.70
GF Value ₹75.10
Valuation Possible Value Trap
! 4 Warning Signs
View Full Analysis

What is Vilin Bio Med EBIT?

Vilin Bio Med NSE:VILINBIO +4.93% 69 EBIT is ₹26.5 Mil as of Mar. 2026. GuruFocus rates NSE:VILINBIO with a GF Score™ of 69/100 and a GF Value™ of ₹75.10 (Possible Value Trap). The stock has 4 warning signs investors should review.

Vilin Bio Med's earnings before interest and taxes (EBIT) for the six months ended in Mar. 2026 was ₹26.5 Mil. Its earnings before interest and taxes (EBIT) for the trailing twelve months (TTM) ended in Mar. 2026 was ₹26.5 Mil.

EBIT or Operating Income is linked to Return on Capital for both regular definition and Joel Greenblatt's definition. Vilin Bio Med's annualized ROC % for the quarter that ended in Mar. 2026 was 12.60%. Vilin Bio Med's annualized ROC (Joel Greenblatt) % for the quarter that ended in Mar. 2026 was 30.41%.

EBIT is also linked to Joel Greenblatt's definition of earnings yield. Vilin Bio Med's Earnings Yield (Joel Greenblatt) % for the quarter that ended in Mar. 2026 was 3.96%.

Vilin Bio Med  (NSE:VILINBIO) EBIT Explanation

1. EBIT or Operating Income is linked to Return on Capital for both regular definition and Joel Greenblatt's definition.

Vilin Bio Med's annualized ROC % for the quarter that ended in Mar. 2026 is calculated as:

ROC % (Q: Mar. 2026 )
=NOPAT/Average Invested Capital
=Operating Income * ( 1 - Tax Rate % )/( (Invested Capital (Q: Mar. 2025 ) + Invested Capital (Q: Mar. 2026 ))/ count )
=52.942 * ( 1 - 32.87% )/( (262.833 + 301.174)/ 2 )
=35.5399646/282.0035
=12.60 %

where

Invested Capital(Q: Mar. 2025 )
=Total Assets - Accounts Payable & Accrued Expense - Excess Cash
=Total Assets - Accounts Payable & Accrued Expense - ( Cash, Cash Equivalents, Marketable Securities - max(0, Total Current Liabilities - Total Current Assets+Cash, Cash Equivalents, Marketable Securities))
=277.279 - 13.885 - ( 0.561 - max(0, 45.7 - 125.606+0.561))
=262.833

Invested Capital(Q: Mar. 2026 )
=Total Assets - Accounts Payable & Accrued Expense - Excess Cash
=Total Assets - Accounts Payable & Accrued Expense - ( Cash, Cash Equivalents, Marketable Securities - max(0, Total Current Liabilities - Total Current Assets+Cash, Cash Equivalents, Marketable Securities))
=349.422 - 33.549 - ( 14.699 - max(0, 64.417 - 273.83+14.699))
=301.174

Note: The Operating Income data used here is two times the semi-annual (Mar. 2026) data.

2. Joel Greenblatt's definition of Return on Capital:

Vilin Bio Med's annualized ROC (Joel Greenblatt) % for the quarter that ended in Mar. 2026 is calculated as:

ROC (Joel Greenblatt) %(Q: Mar. 2026 )
=EBIT/Average of (Net fixed Assets + Net Working Capital)
=EBIT/Average of (Property, Plant and Equipment+Net Working Capital)
     Q: Mar. 2025  Q: Mar. 2026
=EBIT/( ( (Property, Plant and Equipment + Net Working Capital) + (Property, Plant and Equipment + Net Working Capital) )/ count )
=52.964/( ( (28.53 + max(98.676, 0)) + (28.651 + max(192.444, 0)) )/ 2 )
=52.964/( ( 127.206 + 221.095 )/ 2 )
=52.964/174.1505
=30.41 %

where Working Capital is:

Working Capital(Q: Mar. 2025 )
=(Accounts Receivable + Total Inventories + Other Current Assets) - (Accounts Payable & Accrued Expense + Defer. Rev. + Other Current Liabilities)
=(63.057 + 44.118 + 11.468) - (13.885 + 0 + 6.082)
=98.676

Working Capital(Q: Mar. 2026 )
=(Accounts Receivable + Total Inventories + Other Current Assets) - (Accounts Payable & Accrued Expense + Defer. Rev. + Other Current Liabilities)
=(159.562 + 72.153 + 23.087) - (33.549 + 0 + 28.809)
=192.444

When net working capital is negative, 0 is used.

Note: The EBIT data used here is two times the semi-annual (Mar. 2026) EBIT data.

3. It is also linked to Joel Greenblatt's definition of Earnings Yield:

Vilin Bio Med's Earnings Yield (Joel Greenblatt) % for today is calculated as:

Earnings Yield (Joel Greenblatt) %=EBIT (TTM)/Enterprise Value (Q: Mar. 2026 )
=26.482/669.035
=3.96 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Vilin Bio Med EBIT Related Terms

Vilin Bio Med EBIT Historical Data

* Premium members only.

The historical data trend for Vilin Bio Med's EBIT can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Vilin Bio Med EBIT Chart

Vilin Bio Med Annual Data
Trend Mar20 Mar21 Mar22 Mar23 Mar24 Mar25 Mar26
EBIT
Get a 7-Day Free Trial 5.40 24.30 10.06 11.51 29.10

Vilin Bio Med Semi-Annual Data
Mar20 Mar21 Mar22 Sep22 Mar23 Sep23 Mar24 Sep24 Mar25 Mar26
EBIT Get a 7-Day Free Trial Premium Member Only Premium Member Only 14.21 -4.15 5.63 5.88 26.48

NSE:VILINBIO vs ZTS: EBIT Comparison

For the Drug Manufacturers - Specialty & Generic subindustry, Vilin Bio Med's EV-to-EBIT, along with its competitors' market caps and EV-to-EBIT data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Vilin Bio Med EV-to-EBIT vs Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Vilin Bio Med's EV-to-EBIT distribution charts can be found below:

* The bar in red indicates where Vilin Bio Med's EV-to-EBIT falls into.


NSE:VILINBIO
69GF Score
Vilin Bio Med Ltd NSE:VILINBIO
EBIT is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Vilin Bio Med EBIT Calculation

EBIT, sometimes also called Earnings Before Interest and Taxes, is a measure of a firm's profit that includes all expenses except interest and income tax expenses. It is the difference between operating revenues and operating expenses. When a firm does not have non-operating income, then Operating Income is sometimes used as a synonym for EBIT and operating profit.

EBIT for the trailing twelve months (TTM) ended in Mar. 2026 adds up the semi-annually data reported by the company within the most recent 12 months, which was ₹26.5 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about EBIT →
What does a EBIT of ₹26.5 Mil mean?
Vilin Bio Med (NSE:VILINBIO) has a EBIT of ₹26.5 Mil as of Mar. 2026. Earnings before interest and taxes is the difference between operating revenue and operating expenses. View historical data on Vilin Bio Med.
Is Vilin Bio Med's EBIT too high?
Vilin Bio Med's current EBIT is ₹26.5 Mil. Overall, Vilin Bio Med has a GF Score™ of 69/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does Vilin Bio Med's EBIT compare to ZTS?
Vilin Bio Med's EBIT of ₹26.5 Mil can be compared against companies in the Drug Manufacturers industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EBIT for a Drug Manufacturers company?
A good EBIT depends on the Drug Manufacturers industry context. However, EBIT should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EBIT mean?
A high EBIT can signal that a stock is expensive relative to its fundamentals. Earnings before interest and taxes is the difference between operating revenue and operating expenses. View historical data on Vilin Bio Med. Vilin Bio Med's current EBIT is ₹26.5 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Vilin Bio Med stock overvalued right now?
Based on GuruFocus' analysis, Vilin Bio Med (NSE:VILINBIO) is currently considered Possible Value Trap. The stock's GF Value™ is ₹75.10, compared to a current price of ₹44.70 — trading 40.5% below its estimated fair value. The current EBIT is ₹26.5 Mil. Vilin Bio Med's overall GF Score™ is 69/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EBIT calculated?
EBIT is calculated from a company's financial statements. For Vilin Bio Med (NSE:VILINBIO), the current EBIT is ₹26.5 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Vilin Bio Med (NSE:VILINBIO) Overvalued in 2026?

Based on GuruFocus' analysis, Vilin Bio Med stock appears to be undervalued. The current stock price of ₹44.70 is trading 40.5% below its estimated GF Value™ of ₹75.10. GuruFocus considers Vilin Bio Med to be Possible Value Trap.

Key valuation signals for NSE:VILINBIO:

  • EBIT: ₹26.5 Mil
  • GF Value™: ₹75.10 vs. price of ₹44.70 (40.5% below fair value)
  • GF Score™: 69/100 with 4 warning signs

No single metric tells the full story. See the NSE:VILINBIO stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Vilin Bio Med Business Description

Address Road No. 2, Banjara Hills, H. No. 8-2-269/S/43, Plot No. 43, Sagar Co-operative Housing Society, Khairatabad, Hyderabad, TG, IND, 500034
Vilin Bio Med Ltd is engaged in the domestic business of manufacturing Pharmaceuticals products. It is manufacturing pharmaceutical formulations such as Oral Liquids, Dry syrups, Sachets, External Preparations, Beta and Non-Beta Lactam tablets, and Capsules and Nutritional Food supplements.
69GF Score

Get the complete analysis for NSE:VILINBIO

EBIT is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

₹44.70
Price
₹75.10
GF Value